93202-41-6

Upstream product

• 615-16-7 1,3-dihydro-2H-benzimidazol-2-one 
• 79-04-9 chloroacetyl chloride 
• 615-16-7 1H-benzimidazol-2-ol 

Downstream Products

• 1569066-20-1 5-(2-(4-fluoro-2-[(2-methoxyethoxy)methyl]phenyl)thiazol-4-yl)-1H-benzo[d]imidazol-2(3H)-one 
• 1569065-87-7 5-(2-(4-fluoro-2-methylphenyl)thiazol-4-yl)-1H-benzo[d]imidazol-2(3H)-one 

Relevant academic research and scientific papers

KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE

The present invention is directed to kinase inhibitor compounds having the following structure: or a stereoisomer, pharmaceuticallyacceptable salt, oxide, or solvate thereof, where R1, R2, X, n, R3, Y, Z, R4, R

Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity

The Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) is an enzyme that has been implicated as an important drug target in various therapeutic areas, including neurological disorders (Down syndrome, Alzheimer's disease), oncology, and

COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS

Compounds and compositions are presented that inhibit K-ras, and especially mutant K-ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.

HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF

The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.

MIF INHIBITORS

The present invention relates to the use of specific benzimidazolone analogues and derivatives to inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF), and diseases or conditions wherein MIF cytokine or biological activity is implicated. Novel benzimidazole analogues and derivatives are also provided.

Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists

Described are piperidines of Formula I and pharmaceutically acceptable salts thereof. The compounds of Formula I are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, stroke, cerebral ischemia, central nervous system disorders, depression, trauma, hypoglycemia, neurodegenerative disorders, anxiety, migraine headache, convulsions, Parkinson's disease, aminoglycoside antibiotics-induced hearing loss, psychosis, glaucoma, CMV retinitis, opioid tolerance or withdrawal, pain, especially chronic pain, neuropathic pain, or surgical pain, or urinary incontinence.

FRIDEL-CRAFTS ACYLATION OF BENZIMIDAZOLIN-2-ONES WITH ALIPHATIC ACID CHLORIDES

The acylation of benzimidazolin-2-one and its 5,6-disubstituted derivatives with aliphatic acid chlorides in the presence of anhydrous aluminium chloride was studied.The corresponding 5(6)-acyl-, 5-R-6-acyl, and 5,6-dimethyl-4-acylbenzimidazolin-2-ones, the structures of which were confirmed by the results of elementary analysis and IR, PMR, and mass spectroscopy, were obtained.The yields of the acylation products depend on the electronic effects of the substituents in the benzene ring of the benzimidazolin-2-one on steric factors.